Diagnostic Substances
(VIVO) Meridian Bioscience Slashes Outlook For 2010
Life science company, Meridian Bioscience, Inc. (VIVO), recently slashed its outlook for fiscal 2010 (ending Sep 30, 2010) mainly due to a weaker-than-expected H1N1 season and lower C. difficile product revenues.
The...
(AMAG) AMAG Pharmaceuticals Reports Narrower Fourth Quarter Loss
AMAG Pharmaceuticals Inc. (AMAG) reported a fourth-quarter fiscal 2009 net loss of $18.4 million, or $1.07 per share, which was lower than the year-ago loss of $21.8 million, or $1.28. The Zacks Consensus...
(MYGN) Myriad Surpasses Consensus Estimates
Myriad Genetics Inc. (MYGN) reported second quarter fiscal 2010 earnings of 36 cents per share, two cents above the Zacks Consensus Estimate. The company had earned 22 cents in the year-ago period. The year-ago...
(ABAX) Abaxis Thurd Quarter 2010 Report Misses Estimates
Abaxis, Inc. (ABAX) reported third quarter fiscal 2010 earnings per share of 15 cents, missing the Zacks Consensus Estimate of 17 cents. However, earnings in the year-ago quarter were 15 cents.
Sales
(SRDX) SurModics Earnings Report Beats Expectations
SurModics (SRDX) reported first quarter fiscal 2010 earnings per share (EPS) of 11 cents, down from $1.53 in the year ago period. However, after adjustments, the EPS of 24 cents surpassed the Zacks Consensus...
(VIVO) Meridian Bioscience Misses Expectations by a Penny
Recently, Meridian Bioscience Inc. (VIVO) reported results for the first quarter of fiscal 2010. The company earned 22 cents per share in the quarter which fell short of the Zacks Consensus Estimate by a...
(ABAX) Abaxis Receives FDA Approval
Abaxis, Inc. (ABAX) recently received the U.S. Food and Drug Administration (FDA) approval to market its new C-Reactive Protein (CRP) assay in the United States. The new C-Reactive Protein assay is used by...
(AMAG) AMAG Pharmaceuticals Guides on Feraheme
Recently, AMAG Pharmaceuticals Inc. (AMAG) stated that it expects net revenues between $12 and $13 million from its lead anti-anemia injectable product Feraheme for the fourth quarter of fiscal 2009 (ended...
(BLUD) Immucor Beats Earnings Estimates
Immucor (BLUD) announced second quarter 2010 earnings per share of 28 cents, which was better than the Zacks Consensus Estimate of 26 cents and the year-ago quarter’s 24 cents. Net income for the quarter...
(ABAX) Abaxis Launches New Bird Flu Test Product
Abaxis, Inc. (ABAX) reported that it has launched its first product, a rapid Avian Influenza Antigen Test, in the production animal diagnostics market. Avian Influenza Antigen Test is a disposable and USDA-licensed...
(NEOG) Neogen Beats Earnings Expectations by a Penny
Neogen Corp. (NEOG) recently posted fiscal second quarter results. The company’s GAAP net income grew 18% to $4.6 million, compared to $3.9 million in the year-ago period. Adjusting for a 3-for-2 stock...
(MYGN) Myriad Genetics Upgraded to Neutral
We have upgraded Myriad Genetics (MYGN) to Neutral from Underperform based on the impressive performance of its molecular diagnostics business. Effective July 1, 2009, the company spun off its therapeutics...
(MYGN) Myriad Genetics – Bear of the Day
Myriad Genetics Inc. (MYGN) reported first quarter fiscal 2010 earnings of 31 cents per share, which was below the Zacks Consensus Estimate by a penny. The company had earned 25 cents per share in the year-ago...
(MYGN) Myriad Genetics Inc Misses Forecasts by a Penny
Myriad Genetics Inc. (MYGN) reported fiscal first-quarter earnings of 31 cents per share, a penny behind the Zacks Consensus Estimate. The company had earned 25 cents in the...
(SRDX) SurModics Misses Earnings Estimates
SurModics’ (SRDX) fourth-quarter earnings per share came in at 18 cents, below the Zacks Consensus Estimate of 20 cents. The company reported revenues of $19.2 million, down...
(ABAX) Abaxis Earnings Report Lags Consensus Estimates
Abaxis Inc. (ABAX) reported second quarter fiscal 2010 earnings per share of 14 cents, lower than the Zacks Consensus Estimate of 17 cents and the year-ago earnings of 15 cents.
will be purchased by MediciNova, Inc. (MNOV) for $1.24 per share in either cash or secured convertible notes. The deal has been valued at about $37 million.
Approximately...
(MYGN) Biotech Industry – Zacks Analyst Interviews
OVERVIEW
The Biotech industry as a whole continues to underperform the market so far this year. As of May 26, 2009, Both the AMEX Biotech Index and the broader NASDAQ Biotech Index declined 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ...
(MYGN) Myriad Genetics, Inc. – Momentum – Zacks Rank Buy
Myriad Genetics, Inc. (MYGN) continues to head higher after the company reported strong earnings on Feb 3 and announced a 2-for-1 stock split on Feb 24.
Second-Quarter Results
Much of Myriad’s...
(MYGN) Myriad Genetics – Revenues increased 58%, on a year-over-year basis
Myriad Genetics, Inc. (MYGN) has just reported a fantastic quarter and shares have responded. Analysts are responding with sharp increases in earnings estimates.
Company Description
Myriad Genetics uses gene-based medicine to develop therapeutic and molecular...
(MYGN) Myriad Genetics – Revenue increased 53% from last year
Myriad Genetics, Inc.’s (MYGN) share price continues to advance after the company reported a great quarter in early November. Analysts are bullish on the company, with the next-year estimate projecting 60% earnings growth.
Company Description
Myriad Genetics...
(BLUD) Immucor – third consecutive earnings surprise
Immucor Inc.(BLUD) recently reported a company record for net income in a quarter and completed an acquisition. Earnings are showing solid growth for next year and are traded at a fair value.
Company Description
Immucor is an international in vitro diagnostic...